Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “administration”

271 pharma patents match "administration" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 271
Index total 30,257
Page 1 / 12

Quick answer

This filtered view shows 271 pharmaceutical patents matching "administration" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

271 results for “administration” · 30,257 patents in full index Clear search

  1. WO 2026060304

    ADMINISTRATION SOUS-CUTANÉE D'UN AGENT ANTI-DLL3 POUR LE TRAITEMENT DU CANCER

    AMGEN INC [US] · Granted Mar 19, 2026 · Expires Mar 14, 2046

    granted
  2. WO 2026027759

    AGENTS ET MÉTHODES POUR UNE ADMINISTRATION CIBLÉE À DES CELLULES

    BIONTECH SE [DE] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  3. WO 2025262460

    COMPOSITIONS LIPIDIQUES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  4. WO 2025210141

    SYSTÈME D'ADMINISTRATION UTILE POUR L'ADMINISTRATION TOPIQUE D'ARN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Oct 9, 2025 · Expires Oct 4, 2045

    granted
  5. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  6. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  7. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  8. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  9. US 12383572

    Administration of an anti-activin-a compound to a subject

    Atara Biotherapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  10. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  11. US 12357555

    Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase

    INVENTIONBIO SPÓKA Z OGRANICZON ODPOWIEDZIALNOCIA · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  12. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  13. WO 2025133253

    EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE

    ABLYNX NV [BE] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  14. US 12329772

    Methods and compositions for administration of iron

    American Regent, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  15. US 12331099

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  16. WO 2025077836

    LIPIDES IONISABLES ET NANOPARTICULES LIPIDIQUES POUR ADMINISTRATION D'ARN

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 17, 2025 · Expires Apr 12, 2045

    granted
  17. US 12257224

    Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

    Milestone Pharmaceuticals Inc. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  18. US 12226404

    Methods for making compositions for pulmonary administration

    The Board of Regents of the University of Texas System · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  19. US 12214083

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  20. US 2025002606

    Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

    BAVARIAN NORDIC AS [DK] · Granted Jan 2, 2025 · Expires Dec 28, 2044

    granted
  21. US 12178860

    Hyaluronidase enzyme formulations for high volume administration

    HALOZYME, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  22. US 12178981

    Drug administration method

    Takeda Pharmaceutical Company Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  23. US 12102642

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  24. US 12097199

    Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted